多替拉韦用于艾滋病治疗的临床应用  

Clinical Application of Dolutegravir in the Treatment of AIDS

作　　者：肖然[1] 付强[1] 杜小莉[1] 李太生[2,3] XIAO Ran;FU Qiang;DU Xiao-li;LI Tai-sheng(Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;Department of Infectious Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;Tsinghua-Peking Center for Life Sciences,Beijing 100084,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院药剂科,北京100730 [2]中国医学科学院北京协和医学院北京协和医院感染科,北京100730 [3]清华大学-北京大学生命科学联合中心,北京100084

出　　处：《中国药学杂志》2023年第6期544-550,共7页Chinese Pharmaceutical Journal

基　　金：十三五国家科技重大专项课题-艾滋病综合治疗方案的优化及推广应用研究项目资助(2017ZX10202101)。

摘　　要：目的通过分析多替拉韦(DTG)的临床试验数据,为优化基于DTG的抗反转录病毒疗法(ART)提供参考。方法检索国内外有关DTG的文献,对DTG的药效学特性、药动学特性、安全性以及基于DTG的不同ART方案的疗效进行分析总结。结果DTG具有强大的活性、良好的耐受性以及较高的耐药屏障。多项临床试验表明,基于DTG的二联法具有不劣于三联法的疗效和安全性。结论DTG已成为目前ART中的核心药物,基于DTG的二联ART应用前景可观。OBJECTIVE To provide a reference for optimization of antiretroviral therapy(ART)based on dolutegravir(DTG)through analyzing clinical trial data of DTG.METHODS The literature at home and abroad about DTG was retrieved,and the pharmacodynamic properties,pharmacokinetic properties,safety,and efficacy of different DTG-based ART regimens were analyzed and summarized.RESULTS DTG has potent activity,good tolerability,and a high barrier to drug resistance.Multiple clinical trials have shown that DTG-based dual therapies have non-inferior efficacy and safety to triple therapies.CONCLUSION DTG has become the core drug in current ART,and the prospect of DTG-based dual ART is promising.

关 键 词：多替拉韦 整合酶抑制剂 抗反转录病毒疗法 获得性免疫缺陷综合征 艾滋病病毒 

分 类 号：R978.7[医药卫生—药品]